Finance

Lists
DNPUF:OTCMKTS
Sumitomo Pharma Co Ltd
9,79 USD
0,00%
(0,00) 1D
16-сен., 15:47:50 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNPUF...
Mkt. cap
692,97 млд
Avg. vol.
83,00
Volume
0,00
52-wk high
19,20 USD
52-wk low
8,40 USD
Beta
0,38
Shares outstanding
449,20 млн
No. of employees
3 миң
Mkt. cap
692,97 млд
Avg. vol.
83,00
Volume
0,00
52-wk high
19,20 USD
52-wk low
8,40 USD
Beta
0,38
Shares outstanding
449,20 млн
No. of employees
3 миң
News stories
From web sources and news partners
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3,12 миң
Founded1897-ж., 14-май
HeadquartersOsaka, Osaka, Япония
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
119,12 млд
120,62 млд
105,55 млд
129,50 млд
Cost of goods sold
45,59 млд
55,44 млд
51,26 млд
61,41 млд
Cost of revenue
45,59 млд
55,44 млд
51,26 млд
61,41 млд
Research and development expenses
9,35 млд
10,35 млд
16,12 млд
11,43 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40,90 млд
42,94 млд
43,52 млд
39,24 млд
Operating expense
-1,04 млд
52,19 млд
110,09 млд
50,33 млд
Total operating expenses
44,55 млд
107,63 млд
161,36 млд
111,74 млд
Operating income
74,57 млд
13,00 млд
-55,81 млд
17,75 млд
Other non operating income
-
-
-1,64 млд
-
EBT including unusual items
80,87 млд
8,74 млд
-1,20 млд
18,30 млд
EBT excluding unusual items
80,87 млд
8,74 млд
-51,00 млд
18,30 млд
Income tax expense
-6,78 млд
-80,00 млн
-383,00 млн
1,30 млд
Effective tax rate
-8,39%
-0,92%
32,05%
7,09%
Other operating expenses
-51,30 млд
-1,10 млд
50,45 млд
-337,00 млн
Net income
87,65 млд
8,82 млд
-812,00 млн
17,00 млд
Net profit margin
73,58%
7,31%
-0,77%
13,13%
Earnings per share
-
-
-
-
Interest and investment income
5,11 млд
258,00 млн
4,64 млд
2,20 млд
Interest expense
-
-5,14 млд
-
-2,09 млд
Net interest expenses
5,11 млд
-4,88 млд
4,64 млд
107,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
79,85 млд
18,32 млд
-52,48 млд
22,65 млд
Gain or loss from assets sale
1,96 млд
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору